July 13, 2016 | Juno Therapeutics has been given the green light to re-start a cancer clinical trial less than a week after regulators put it on hold because of three patient deaths. The Seattle biotech company, a leader in the emerging field of engineered T-cell immunotherapy for cancer, said today the FDA has allowed it to start enrolling patients once again. Forbes